Ginkgo Bioworks Holdings (DNA) EBT Margin (2020 - 2025)
Historic EBT Margin for Ginkgo Bioworks Holdings (DNA) over the last 6 years, with Q3 2025 value amounting to 207.93%.
- Ginkgo Bioworks Holdings' EBT Margin fell 1441700.0% to 207.93% in Q3 2025 from the same period last year, while for Sep 2025 it was 188.29%, marking a year-over-year increase of 1106500.0%. This contributed to the annual value of 241.15% for FY2024, which is 1139600.0% up from last year.
- According to the latest figures from Q3 2025, Ginkgo Bioworks Holdings' EBT Margin is 207.93%, which was down 1441700.0% from 122.13% recorded in Q2 2025.
- In the past 5 years, Ginkgo Bioworks Holdings' EBT Margin ranged from a high of 63.76% in Q3 2024 and a low of 1081.31% during Q4 2021
- Its 5-year average for EBT Margin is 357.98%, with a median of 245.99% in 2024.
- Per our database at Business Quant, Ginkgo Bioworks Holdings' EBT Margin plummeted by -9366000bps in 2021 and then surged by 8901800bps in 2022.
- Quarter analysis of 5 years shows Ginkgo Bioworks Holdings' EBT Margin stood at 1081.31% in 2021, then surged by 82bps to 191.13% in 2022, then plummeted by -219bps to 609.67% in 2023, then surged by 60bps to 245.99% in 2024, then rose by 15bps to 207.93% in 2025.
- Its EBT Margin stands at 207.93% for Q3 2025, versus 122.13% for Q2 2025 and 188.06% for Q1 2025.